Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma

Kobayashi, Hideaki; Ishii, Yoshinori; Takayama, Tadatoshi

doi:10.1002/jso.20257

Cited by 94 publications

(79 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kobayashi et al (48) described that LAT1 expression in esophageal carcinoma was higher in cancerous tissue than in noncancerous tissue, and the expression increased in relation to depth of invasion, maximum tumor diameter, and differentiation. In our study, LAT1 expression did not increase in connection with pleural involvement, lymphatic permeation, vascular invasion, or lymph node metastasis.…”

Section: Discussionmentioning

confidence: 99%

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study

Kaira

Oriuchi²,

Otani³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study

Kaira

Oriuchi²,

Otani³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

“…Previous studies have shown that LAT1 is often excessively expressed in primary human neoplasms of various organs and is involved in tumor cell proliferation due to its function in transporting essential amino acids (4)(5)(6). Previous studies have demonstrated the upregulation of LAT1 immunohistochemically in prostate cancers (7), as well as in squamous cell carcinomas (8,9), gliomas (10), urothelial carcinomas (11), non-small cell lung cancers (12,13), breast cancers (14) and pancreatic cancers (15). In their previous study, Sakata et al (7) suggested that elevated LAT1 expression in prostate cancer core needle biopsy samples may be considered a novel biomarker for high-grade malignancy, but did not clarify the correlation between LAT1 expression and Gleason score, the most commonly used tool for grading the malignancy of prostate cancers.…”

Section: Introductionmentioning

confidence: 99%

L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer

Segawa

Nagamori

Kanai

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Upregulation of L-type amino acid transporter 1 (LAT1), a member of the system L amino acid transporter family, may be detected by immunohistochemical methods. Immunoreactive LAT1 expression in prostate cancer is considered to be a promising biomarker for high-grade malignancy. However, the mutual association between LAT1 and Gleason score, the most fixed indicator for grading the malignancy of prostate cancers, remains to be elucidated. The aim of this study was to clarify the correlations between LAT1 and other factors in prostate cancer, including the Gleason score. We evaluated 54 cases of primary prostate cancer, surgically resected without any neoadjuvant therapies and performed immunohistochemistry for LAT1, Ki-67, CD34 and vascular endothelial growth factor on the tissue sections. The Gleason score as well as the age, pathological stage (pStage) of prostate cancer and serum concentration of prostate-specific antigen (PSA) of each case were also assessed. Statistical analysis for the correlations between LAT1 expression and Gleason score and each of the other characteristics studied was performed. As a result, a strong significant correlation between immunoreactive LAT1 expression and Gleason score was identified (P<0.01). We concluded that immunoreactive LAT1 expression in tissue sections of prostate cancer may be useful as a biomarker for high-grade malignancy.

show abstract

“…L-type amino acid transporter 1 (LAT1) is a neutral amino acid transporter and is essential for the transport of large neutral amino acids [6,7]. It has been shown that LAT1 is overexpressed in some malignant tumor cells such as KB human oral epidermoid carcinoma cells [8], esophageal carcinoma [9], Barrett's adenocarcinoma [10], astrocytic tumors [11,12], lung adenocarcinoma [13], oral cancer [14] and osteogenic sarcoma cells [15]. Amino acids are essential for protein synthesis, which is required for critical cell growth and proliferation [16].…”

Section: Introductionmentioning

confidence: 99%

Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression

Liang

Cho

Williams

et al. 2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose L-type amino acid transporter 1 (LAT1) is essential for the transport of large neutral amino acids. However, its role in breast cancer growth remains largely unknown. The purpose of the study is to investigate whether LAT1 is a potential biomarker for the diagnosis and treatment of breast cancer. Methods LAT1 mRNA and protein levels in breast cancer cell lines and tissues were analyzed. In addition, the effects of targeting LAT1 for the inhibition of breast cancer cell tumorigenesis were assessed with soft agar assay. The imaging of xenograft with anti-1-amino-3-[ 18 F]fluorocyclobutane-1-carboxylic acid (anti-[ 18 F]FACBC) PET was assessed for its diagnostic biomarker potential. Results Normal breast tissue or low malignant cell lines expressed low levels of LAT1 mRNA and protein, while highly malignant cancer cell lines and high-grade breast cancer tissue expressed high levels of LAT1. In addition, higher expression levels of LAT1 in breast cancer tissues were consistent with advanced-stage breast cancer. Furthermore, the blockade of LAT1 with its inhibitor, 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH), or the knockdown of LAT1 with siRNA, inhibited proliferation and tumorigenesis of breast cancer cells. A leucine analog, anti-[ 18 F]FACBC, has been demonstrated to be an excellent PET tracer for the non-invasive imaging of malignant breast cancer using an orthotopic animal model. Conclusions The overexpression of LAT1 is required for the progression of breast cancer. LAT1 represents a potential biomarker for therapy and diagnosis of breast cancer. Anti-[ 18 F]FACBC that correlates with LAT1 function is a potential PET tracer for malignant breast tumor imaging.

show abstract

Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma

Abstract: These results suggest that LAT1 plays a significant role in cell proliferation, differentiation, and invasion in esophageal squamous cell carcinoma.

Cited by 94 publications

References 10 publications

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study

L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer

Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression

Contact Info

Product

Resources

About